These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. CRISPR/dCas9-based Scn1a gene activation in inhibitory neurons ameliorates epileptic and behavioral phenotypes of Dravet syndrome model mice. Yamagata T; Raveau M; Kobayashi K; Miyamoto H; Tatsukawa T; Ogiwara I; Itohara S; Hensch TK; Yamakawa K Neurobiol Dis; 2020 Jul; 141():104954. PubMed ID: 32445790 [TBL] [Abstract][Full Text] [Related]
3. Targeted Augmentation of Nuclear Gene Output (TANGO) of Scn1a rescues parvalbumin interneuron excitability and reduces seizures in a mouse model of Dravet Syndrome. Wengert ER; Wagley PK; Strohm SM; Reza N; Wenker IC; Gaykema RP; Christiansen A; Liau G; Patel MK Brain Res; 2022 Jan; 1775():147743. PubMed ID: 34843701 [TBL] [Abstract][Full Text] [Related]
4. Impairment of Sharp-Wave Ripples in a Murine Model of Dravet Syndrome. Cheah CS; Lundstrom BN; Catterall WA; Oakley JC J Neurosci; 2019 Nov; 39(46):9251-9260. PubMed ID: 31537705 [TBL] [Abstract][Full Text] [Related]
5. Sexually Divergent Mortality and Partial Phenotypic Rescue After Gene Therapy in a Mouse Model of Dravet Syndrome. Niibori Y; Lee SJ; Minassian BA; Hampson DR Hum Gene Ther; 2020 Mar; 31(5-6):339-351. PubMed ID: 31830809 [TBL] [Abstract][Full Text] [Related]
6. Cell-Selective Adeno-Associated Virus-Mediated Tanenhaus A; Stowe T; Young A; McLaughlin J; Aeran R; Lin IW; Li J; Hosur R; Chen M; Leedy J; Chou T; Pillay S; Vila MC; Kearney JA; Moorhead M; Belle A; Tagliatela S Hum Gene Ther; 2022 Jun; 33(11-12):579-597. PubMed ID: 35435735 [TBL] [Abstract][Full Text] [Related]
7. Antisense oligonucleotides restore excitability, GABA signalling and sodium current density in a Dravet syndrome model. Yuan Y; Lopez-Santiago L; Denomme N; Chen C; O'Malley HA; Hodges SL; Ji S; Han Z; Christiansen A; Isom LL Brain; 2024 Apr; 147(4):1231-1246. PubMed ID: 37812817 [TBL] [Abstract][Full Text] [Related]
8. Scn1a gene reactivation after symptom onset rescues pathological phenotypes in a mouse model of Dravet syndrome. Valassina N; Brusco S; Salamone A; Serra L; Luoni M; Giannelli S; Bido S; Massimino L; Ungaro F; Mazzara PG; D'Adamo P; Lignani G; Broccoli V; Colasante G Nat Commun; 2022 Jan; 13(1):161. PubMed ID: 35013317 [TBL] [Abstract][Full Text] [Related]
9. A Transient Developmental Window of Fast-Spiking Interneuron Dysfunction in a Mouse Model of Dravet Syndrome. Favero M; Sotuyo NP; Lopez E; Kearney JA; Goldberg EM J Neurosci; 2018 Sep; 38(36):7912-7927. PubMed ID: 30104343 [TBL] [Abstract][Full Text] [Related]
10. A selective Na Chow CY; Chin YKY; Ma L; Undheim EAB; Herzig V; King GF Biochem Pharmacol; 2020 Nov; 181():113991. PubMed ID: 32335140 [TBL] [Abstract][Full Text] [Related]
11. Ndnf Interneuron Excitability Is Spared in a Mouse Model of Dravet Syndrome. Liebergall SR; Goldberg EM J Neurosci; 2024 Apr; 44(17):. PubMed ID: 38443186 [TBL] [Abstract][Full Text] [Related]
12. Genetic background modulates impaired excitability of inhibitory neurons in a mouse model of Dravet syndrome. Rubinstein M; Westenbroek RE; Yu FH; Jones CJ; Scheuer T; Catterall WA Neurobiol Dis; 2015 Jan; 73():106-17. PubMed ID: 25281316 [TBL] [Abstract][Full Text] [Related]
13. Preictal dysfunctions of inhibitory interneurons paradoxically lead to their rebound hyperactivity and to low-voltage-fast onset seizures in Dravet syndrome. Capitano F; Kuchenbuch M; Lavigne J; Chaptoukaev H; Zuluaga MA; Lorenzi M; Nabbout R; Mantegazza M Proc Natl Acad Sci U S A; 2024 Jun; 121(23):e2316364121. PubMed ID: 38809712 [TBL] [Abstract][Full Text] [Related]
14. Electrophysiological Alterations of Pyramidal Cells and Interneurons of the CA1 Region of the Hippocampus in a Novel Mouse Model of Dravet Syndrome. Dyment DA; Schock SC; Deloughery K; Tran MH; Ure K; Nutter LMJ; Creighton A; Yuan J; Banderali U; Comas T; Baumann E; Jezierski A; ; Boycott KM; Mackenzie AE; Martina M Genetics; 2020 Aug; 215(4):1055-1066. PubMed ID: 32554600 [TBL] [Abstract][Full Text] [Related]
15. Knock-in model of Dravet syndrome reveals a constitutive and conditional reduction in sodium current. Schutte RJ; Schutte SS; Algara J; Barragan EV; Gilligan J; Staber C; Savva YA; Smith MA; Reenan R; O'Dowd DK J Neurophysiol; 2014 Aug; 112(4):903-12. PubMed ID: 24805083 [TBL] [Abstract][Full Text] [Related]
16. Preferential expression of SCN1A in GABAergic neurons improves survival and epileptic phenotype in a mouse model of Dravet syndrome. Ricobaraza A; Bunuales M; Gonzalez-Aparicio M; Fadila S; Rubinstein M; Vides-Urrestarazu I; Banderas J; Sola-Sevilla N; Sanchez-Carpintero R; Lanciego JL; Roda E; Honrubia A; Arnaiz P; Hernandez-Alcoceba R J Mol Med (Berl); 2023 Dec; 101(12):1587-1601. PubMed ID: 37819378 [TBL] [Abstract][Full Text] [Related]
17. Vasoactive intestinal peptide-expressing interneurons are impaired in a mouse model of Dravet syndrome. Goff KM; Goldberg EM Elife; 2019 Jul; 8():. PubMed ID: 31282864 [TBL] [Abstract][Full Text] [Related]
20. Impaired excitability of somatostatin- and parvalbumin-expressing cortical interneurons in a mouse model of Dravet syndrome. Tai C; Abe Y; Westenbroek RE; Scheuer T; Catterall WA Proc Natl Acad Sci U S A; 2014 Jul; 111(30):E3139-48. PubMed ID: 25024183 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]